Kezar Life Sciences to Present Complete Results from the Phase 2 MISSION Trial of Zetomipzomib in Patients with Lupus Nephritis at the American Society of Nephrology’s Kidney Week 2022 Annual Meeting October 14, 2022 PDF Version SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 14, 2022-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that four posters will be presented at the upcoming American Society of Nephrology’s (ASN) Kidney Week 2022 Annual Meeting, which will take place November 3 – 6, 2022 in Orlando, FL. Of note, the Phase 2 MISSION poster will include the full data set from the concluded study, with all 17 evaluable patients completing the 37-week trial. There will be additional MISSION data included in the poster presentation that are not available in the abstract. Poster Presentation Details: Abstract Title: Zetomipzomib (KZR-616), A First-in-Class Selective Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis: Preliminary Results from the Phase 2 MISSION Study Session: Glomerular Diseases: Clinical, Outcomes, Trials - I [PO1303-1] Date/Time: November 3, 2022 from 10:00 AM - 12:00 PM ET Presenter: Dr. Samir V. Parikh, MD, Associate Professor of Medicine, Division of Nephrology, The Ohio State University Wexner Medical Center Abstract Title: Comorbidities and Poor Long-Term Outcomes of Lupus Nephritis in Adult Patients in the United States Session: Glomerular Diseases: Lupus and Vasculitis [PO1302-2] Date/Time: November 4, 2022 from 10:00 AM - 12:00 PM ET Presenter: Dr. Isabelle Ayoub, MD, Associate Professor of Clinical Medicine, Division of Nephrology, The Ohio State University Wexner Medical Center Abstract Title: Poor Health-Related Quality of Life in Adult Patients with Lupus Nephritis Session: Glomerular Diseases: Lupus and Vasculitis [PO1302-2] Date/Time: November 4, 2022 from 10:00 AM - 12:00 PM ET Presenter: Dr. Y. K. O. Teng, MD, PhD, Department of Nephrology, Leiden University Medical Center Abstract Title: Substantial Economic Burden Associated with the Management of Lupus Nephritis in Adult Patients in the United States Session: Glomerular Diseases: Lupus and Vasculitis [PO1302-2] Date/Time: November 4, 2022 from 10:00 AM - 12:00 PM ET Presenter: Dr. Brad Rovin, MD, FASN, FACP, Professor of Medicine and Pathology, The Lee A. Hebert Professor of Nephrology, Director, Division of Nephrology, The Ohio State University Wexner Medical Center The accepted ASN abstracts will be made available today on the congress platform here. Following the conference, the presentation materials will be available in the “Scientific Publications” section of Kezar Life Science’s website at www.kezarlifesciences.com. About Zetomipzomib (KZR-616) Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from Phase 1 clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20221014005025/en/ Investor Contact: Gitanjali Jain Vice President, Investor Relations and External Affairs gjain@kezarbio.com Media Contact: Julia Deutsch Solebury Strategic Communications jdeutsch@soleburystrat.com Source: Kezar Life Sciences, Inc.